Advancing drug discovery using the power of the human genome.

Abstract

Human genetics plays an increasingly important role in drug development and population health. Here we review the history of human genetics in the context of accelerating the discovery of therapies, present examples of how human genetics evidence supports successful drug targets, and discuss how polygenic risk scores could be beneficial in various clinical settings. We highlight the value of direct-to-consumer platforms in the era of fast-paced big data biotechnology, and how diverse genetic and health data can benefit society. © 2021 23andMe, Inc. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

• Authors: Karl Heilbron, Sahar V Mozaffari, Vladimir Vacic, Peng Yue, Wei Wang, Jingchunzi Shi, Adrian M Jubb, Steven J Pitts, Xin Wang
• Journal: The Journal of pathology (J Pathol) Vol. 254 Issue 4 Pg. 418-429 (07 2021) ISSN: 1096-9896 [Electronic] England
• PMID: 33748968 (Publication Type: Journal Article, Review)
• Copyright: © 2021 23andMe, Inc. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Topics

• Drug Discovery
• Genome, Human
• Humans